Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200
Debt
Debt-to-Equity RatioN/A
Current Ratio18.62
Quick Ratio18.62
Price-To-Earnings
Trailing P/E Ratio-0.84
Forward P/E Ratio-1.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.24 million
Price / Sales61.75
Cash FlowN/A
Price / CashN/A
Book Value$3.87 per share
Price / Book0.65
Profitability
EPS (Most Recent Fiscal Year)($2.97)
Net Income$-90,130,000.00
Net Margins-6,640.16%
Return on Equity-56.60%
Return on Assets-51.74%
Miscellaneous
Employees53
Outstanding Shares30,630,000
Market Cap$79.64 million
Otonomy (NASDAQ:OTIC) Frequently Asked Questions
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy Inc (NASDAQ:OTIC) posted its earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.06. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.30 million. Otonomy had a negative net margin of 6,640.16% and a negative return on equity of 56.60%. View Otonomy's Earnings History.
When is Otonomy's next earnings date?
What price target have analysts set for OTIC?
3 Wall Street analysts have issued 12 month price objectives for Otonomy's stock. Their forecasts range from $8.00 to $10.00. On average, they expect Otonomy's share price to reach $9.00 in the next year. This suggests a possible upside of 260.0% from the stock's current price. View Analyst Price Targets for Otonomy.
What is the consensus analysts' recommendation for Otonomy?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Otonomy.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include ZIOPHARM Oncology (ZIOP), Innate Pharma (IPHYF), Selecta Biosciences (SELB), Kala Pharmaceuticals (KALA), Geron (GERN), Evelo Biosciences (EVLO), Clementia Pharmaceuticals (CMTA), MannKind (MNKD), AVEO Pharmaceuticals (AVEO), Paratek Pharmaceuticals (PRTK), Kadmon (KDMN), BIOFRONTERA AG/ADR (BFRA), Proteostasis Therapeutics (PTI), Unum Therapeutics (UMRX) and Athersys (ATHX).
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Dr. Jay B. Lichter, Co-Founder & Chairman (Age 56)
- Dr. David Allen Weber, Pres, CEO & Director (Age 58)
- Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 56)
- Dr. Kathie M. Bishop, Chief Scientific Officer (Age 52)
- Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
Who are Otonomy's major shareholders?
Otonomy's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Manhattan Co. (5.78%). Company insiders that own Otonomy stock include Carl Lebel and Eric J Loumeau. View Institutional Ownership Trends for Otonomy.
Which major investors are selling Otonomy stock?
How do I buy shares of Otonomy?
Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of OTIC stock can currently be purchased for approximately $2.50.
How big of a company is Otonomy?
Otonomy has a market capitalization of $79.64 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.
What is Otonomy's official website?
How can I contact Otonomy?
Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]
MarketBeat Community Rating for Otonomy (NASDAQ OTIC)
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
